Conveners
Session 2 (cn't of Session 1) - Radiopharmaceutical Chemistry (radiodiagnostics, radiotherapy, theragnostics)
- Jean-Francois Chatal (GIP ARRONAX, France)
- Marco Chinol (European Institute of Oncology, Italy)
-
Prof. Jörg Steinbach (Helmholtz-Zentrum Dresden-Rossendorf, Germany)17/09/2012, 14:00Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsInvited LectureDiagnostic radiopharmacy has a long-term development since the early investigations of G. v. Hevesy/ F. A. Paneth and the routine availability of radionuclides. After the age of gamma-emitting radiopharmaceuticals, which are still the working horses of nuclear medicine, in the late seventies a new radiochemical/radiopharmaceutical progression started: The era of Positron Emission Tomography...Go to contribution page
-
Dr Johannes Ermert (Forschungszentrum Juelich GmbH, Institut fuer Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Germany)17/09/2012, 14:20Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsInvited LectureFluorine-18 is a widely used positron-emitting radionuclide in positron emission tomography (PET) because of its ideal decay characteristics. It decays by positron emission (97%) with a relatively low energy of maximum 0.635 MeV ensuring highest possible resolution. The half-life of 109.7 min permits extended syntheses of 18F-labelled radiopharmaceuticals and study protocols. Fluorine-18 is...Go to contribution page
-
Dr Naga Vara Kishore Pillarsetty (Memorial Sloan-Kettering Cancer Center, USA)17/09/2012, 14:40Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsInvited LectureIodine isotopes (I-123, I-125 & I-131) have greatly contributed toward expanding the applications of isotopes in medicine; these applications range from ex vivo radioimmuno assays to in vivo SPECT imaging. Iodine-124 (t1/2 = 4.2 d; b+ 23%) was long considered an impurity in iodine-123 production, has lately seen a renaissance in its applications as a PET isotope in clinics due to the ability...Go to contribution page
-
Prof. Jan Rijn Zeevaart (Necsa, South Africa)17/09/2012, 15:00Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsInvited LectureThe use of radionuclides as potential therapeutic radiopharmaceuticals is increasingly investigated. An important aspect is the delivery of the radionuclide to the target whereby the radionuclide is not lost from the chelating agent. For in vivo generators it is important whether the daughter radionuclide stays inside the chelator after decay of the parent radionuclide. In our previous work,...Go to contribution page
-
Prof. Michael Zalutsky (Duke University, USA)17/09/2012, 15:20Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsInvited LectureThe heavy halogen 211At, first proposed for use in α-particle targeted radiotherapy more than 30 years ago, continues to be one of the most promising radionuclides for this purpose. Its 7.2-h half life provides some flexibility with regard to the range of molecular carriers with compatible pharmacokinetics including antibody fragments, peptides, affibodies and organic molecules. Its diverse...Go to contribution page
-
Dr Antonia Denkova (TU Delft, Netherlands)17/09/2012, 15:40Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsOral CommunicationsAlpha radionuclide therapy has a great potential in the fight against cancer as proven by a large number of pre-clinical and clinical studies [1, 2]. In vivo generators capable of delivering a highly efficient cascade of alpha particles are also steadily gaining importance. 225Ac is at the moment the most important radionuclide that can serve as an in vivo generator, providing four alpha...Go to contribution page
-
Mr Holger Dorrer (Paul Scherrer Institut, Villigen-PSI, Switzerland & University of Bern, Berne, Switzerland)17/09/2012, 15:55Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsOral CommunicationsIntroduction: Terbium provides 4 radioisotopes, which are suitable for different diagnostic or therapeutic applications in nuclear medicine. These are 149Tb (T½ 4.1 h, Eα 3.97 MeV, Iα 16.7 %) for α–radionuclide therapy, 152Tb (T½ 17.5 h, Eβ+,av 1.08 MeV, Iβ+ 17 %) for PET, 155Tb...Go to contribution page
-
Dr Stefaan Pommé (EC-JRC-IRMM, Belgium)17/09/2012, 16:10Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsOral Communications213Bi is one of the most important &alpha-emitting nuclides used in targeted alpha therapy (TAT) against cancer. It is readily available from the subsequent &alpha-decay of 225Ac → 221Fr → 217At → 213Bi. The parent half-life is T1/2(225Ac)=9.920 (3) d (Pommé et al., in press), while 221Fr and...Go to contribution page
-
Prof. Aleksander Bilewicz (Institute of Nuclear Chemistry and Technology, Poland)17/09/2012, 16:25Radiopharmaceutical chemistry, radiodiagnostics, radiotherapy, theragnosticsOral CommunicationsRa-223, Ra-224 and Ra-225, among others alpha-emitting radionuclides, have attractive properties for use in targeted radionuclide therapy. Unfortunately, Ra2+ cations like other cations of the II group, forms very weak complexes, therefore labeling of the biomolecules with 223,224,225Ra is a very difficult task. On the other hand, some zeolites exhibit very high affinity for Ra2+ cations. In...Go to contribution page
-
Mrs Maruta Bunka (Laboratory of Radiochemistry and Environmental Chemistry, Villigen PSI, Switzerland)17/09/2012, 16:40Nuclear Chemistry, Radionuclide Production, High-Power TargetryOral CommunicationsIntroduction: 44Sc with a half-life of 3,97 h and a positron branching of 94 % is a promising nuclide for novel PET-radiopharmaceuticals. With an oxidation state of +3 44Sc may be used for radiolabeling of biomolecules with chelators established for coordination of lanthanides such as 177Lu and for other clinically employed radionuclides such as 90Y, 111In or 68Ga. At the Paul Scherrer...Go to contribution page